Oleoylethanolamide (OEA) — Safety, Research, Risks & Legal Status

Not medical advice. Oleoylethanolamide (OEA) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	OEA, N-oleoylethanolamine, N-oleoyl ethanolamine, cis-9-octadecenoic acid ethanolamide, N-(2-hydroxyethyl)oleamide
Category	Supplement
Compound class	Endogenous N-acylethanolamine (bioactive lipid); anandamide analog
Primary target	PPAR-alpha agonist (secondary: GPR119, TRPV1, GPR55 in experimental systems)
Origin in body	Synthesized in small-intestine enterocytes from dietary oleic acid (NAPE-PLD; CD36-dependent)
Regulatory status (US)	Marketed as a dietary supplement; NDI notification acknowledged ~2015; not an FDA-approved drug
Route	Oral (capsule/powder); low expected bioavailability due to first-pass metabolism
Typical trial dose	~125 mg twice daily (~250 mg/day) for 6 to 8 weeks (informational, not a protocol)
US legal status	In the United States, OEA is an endogenous lipid marketed as a dietary supplement ingredient. A New Dietary Ingredient (NDI) notification was filed with the FDA and receipt was acknowledged around 2015; acknowledgment of an NDI notification is a procedural step, not FDA "approval," and does not constitute an endorsement of safety or efficacy. OEA is not an FDA-approved drug and holds no approved therapeutic indication. In the European Union it is not an authorized novel food, so it cannot be lawfully sold there as a food or food supplement without going through the Novel Food authorization process. Structure/function marketing (for example "supports satiety") is permitted in the US; disease-treatment claims are not. Informational only, not legal advice, and status can differ by jurisdiction and change over time.

What is Oleoylethanolamide (OEA)?

Oleoylethanolamide (OEA) is a naturally occurring signaling lipid, a member of the N-acylethanolamine (NAE) family and a monounsaturated structural relative of the endocannabinoid anandamide. Unlike anandamide, it does not meaningfully activate cannabinoid receptors; its best-characterized molecular target is the nuclear receptor PPAR-alpha. OEA is produced in the lining of the small intestine in response to dietary fat and acts as a peripheral satiety signal, contributing to the sensation that a meal has been consumed. As a supplement it is sold in oral capsule or powder form and marketed mainly for appetite control, weight management, and lipid/metabolic support. It is best understood as a plausible, mechanistically grounded metabolic modulator with modest rather than dramatic human evidence to date.

How it works

OEA's primary proposed mechanism is agonism of PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear transcription factor that upregulates genes for fatty-acid transport, mitochondrial beta-oxidation, and energy metabolism, and drives the anorectic (appetite-suppressing) signal. Endogenously, OEA is synthesized in enterocytes of the proximal small intestine from dietary oleic acid via NAPE-PLD, in a process shown to depend on the fat-transporter CD36, and is degraded by FAAH and NAAA. The satiety signal is thought to be transmitted peripherally: locally produced OEA engages PPAR-alpha and sensory (vagal) afferents, with downstream signaling reaching hypothalamic and brainstem (nucleus tractus solitarius) circuits and involving oxytocin and histaminergic pathways. Secondary targets have been proposed, including GPR119 (linked to GLP-1 release), and OEA also interacts with TRPV1 and GPR55 in experimental systems. Whether orally dosed OEA reaches the brain directly is debated; a 2023 review framed the question explicitly as "to brain or not to brain," favoring a predominantly peripheral mode of action. These mechanisms are well supported in rodents; human confirmation is partial.

Background & history

OEA was identified as a bioactive N-acylethanolamine and its anorexic, weight-reducing properties in rodents were characterized in the early 2000s, most prominently by Daniele Piomelli and colleagues, who linked its satiety effect to PPAR-alpha activation (a landmark finding published around 2003). The subsequent two decades established the intestinal biosynthesis pathway (NAPE-PLD, CD36 dependence) and the FAAH/NAAA degradation route, and positioned OEA within the broader endocannabinoid-related lipid signaling field alongside anandamide and palmitoylethanolamide (PEA). Commercial interest as a "natural" appetite and weight-management supplement followed, with a US NDI notification acknowledged around 2015. Human clinical testing has been modest and relatively recent, expanding from 2016 onward through small metabolic trials, and continues into 2025 to 2026 with meta-analytic synthesis and exploratory extensions into mood and inflammatory conditions.

What the research says

Human data on oral OEA exist but are limited in volume and heavily clustered. The most-cited randomized, double-blind, placebo-controlled trials come largely from a small number of research groups (notably in Tabriz, Iran), dosing obese or metabolically impaired adults with roughly 125 mg twice daily (about 250 mg/day) over 6 to 8 weeks. These reported modest reductions in body weight, BMI, waist circumference, and appetite ratings, increased PPAR-alpha gene expression, and improvements in inflammatory and oxidative-stress markers, glycemic indices (fasting glucose, insulin, HOMA-IR), and lipid profile. A 2025 systematic review and meta-analysis of randomized controlled trials pooled these signals and found generally favorable but small cardiometabolic effects, while noting a limited number of trials, small sample sizes, short durations, and geographic concentration that constrain confidence. Additional small trials cover prediabetes, NAFLD, PCOS, and a 2026 exploratory trial reporting improved mood and reduced fatigue in veterans with Gulf War Illness. Most mechanistic and dose-ranging work is preclinical (rodent). There are no large, long-term, multi-center outcome trials, and independent replication outside the originating groups is thin. Net: promising and biologically coherent, but not established.

Reported effects

Reduced appetite and increased satiety (delayed meal onset, smaller meals in animal models; modest subjective appetite reduction in human trials)
Modest reductions in body weight, BMI, and waist circumference reported in some obese-population RCTs
Increased fatty-acid oxidation and reduced fat storage via PPAR-alpha activation (mechanistic/preclinical, plus gene-expression changes in humans)
Improvements in lipid profile and glycemic markers in some trials (lower fasting glucose, insulin, HOMA-IR)
Reduced markers of inflammation and oxidative stress in obese and NAFLD cohorts
Reported mood improvement and reduced fatigue in one small exploratory trial (Gulf War Illness), not yet replicated

Dosing & administration (informational)

Informational only, not a protocol or a recommendation. In the published human trials, the most common regimen was approximately 125 mg taken twice daily, totaling about 250 mg per day, given orally for 6 to 8 weeks; this is the range that appears repeatedly in the metabolic RCT literature. Some supplement products are marketed at similar or higher single daily doses. Rodent tolerability studies used far higher body-weight-scaled doses without overt toxicity, but animal dosing does not translate directly to humans, and oral human bioavailability is uncertain. Because OEA is metabolically active and the durable-safety database is thin, decisions about whether and how to use it should be made with a qualified clinician who knows the individual's health status and medications. This entry does not provide individualized dosing guidance.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Generally well tolerated in short human trials; because it is an endogenous molecule, it has an inherently plausible safety profile, but long-term safety data in humans are lacking
Reported side effects are uncommon and typically mild, and may include headache and difficulty sleeping
No large or long-duration human safety trials exist; most safety reassurance comes from short (6 to 8 week) studies and animal data
Oral bioavailability is expected to be low due to first-pass hepatic metabolism and rapid enzymatic breakdown (FAAH/NAAA), so systemic exposure from supplements is uncertain and product-dependent
Safety in pregnancy, breastfeeding, in children, or in significant liver/kidney disease has not been established; avoid without clinician oversight
As a PPAR-alpha-active and metabolically active agent, effects on blood glucose and lipids could theoretically interact with metabolic medications
This site does not sell OEA and does not provide medical advice; consult a qualified clinician before use

Drug & supplement interactions

F
o
r
m
a
l
h
u
m
a
n
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
f
o
r
O
E
A
a
r
e
e
s
s
e
n
t
i
a
l
l
y
a
b
s
e
n
t
,
s
o
i
n
t
e
r
a
c
t
i
o
n
r
i
s
k
i
s
i
n
f
e
r
r
e
d
f
r
o
m
m
e
c
h
a
n
i
s
m
.
B
e
c
a
u
s
e
O
E
A
a
c
t
i
v
a
t
e
s
P
P
A
R
-
a
l
p
h
a
a
n
d
h
a
s
b
e
e
n
a
s
s
o
c
i
a
t
e
d
w
i
t
h
l
o
w
e
r
f
a
s
t
i
n
g
g
l
u
c
o
s
e
,
i
n
s
u
l
i
n
,
a
n
d
i
m
p
r
o
v
e
d
l
i
p
i
d
s
i
n
t
r
i
a
l
s
,
i
t
c
o
u
l
d
i
n
t
h
e
o
r
y
a
d
d
t
o
t
h
e
e
f
f
e
c
t
s
o
f
a
n
t
i
d
i
a
b
e
t
i
c
d
r
u
g
s
(
r
a
i
s
i
n
g
a
t
h
e
o
r
e
t
i
c
a
l
h
y
p
o
g
l
y
c
e
m
i
a
c
o
n
s
i
d
e
r
a
t
i
o
n
)
a
n
d
l
i
p
i
d
-
m
o
d
i
f
y
i
n
g
a
g
e
n
t
s
s
u
c
h
a
s
f
i
b
r
a
t
e
s
(
w
h
i
c
h
a
r
e
t
h
e
m
s
e
l
v
e
s
P
P
A
R
-
a
l
p
h
a
a
g
o
n
i
s
t
s
)
.
C
o
m
b
i
n
i
n
g
i
t
w
i
t
h
o
t
h
e
r
a
p
p
e
t
i
t
e
-
s
u
p
p
r
e
s
s
i
n
g
o
r
G
L
P
-
1
-
r
e
l
a
t
e
d
i
n
t
e
r
v
e
n
t
i
o
n
s
h
a
s
n
o
t
b
e
e
n
s
t
u
d
i
e
d
f
o
r
a
d
d
i
t
i
v
e
e
f
f
e
c
t
o
r
s
a
f
e
t
y
.
A
s
a
n
u
n
s
a
t
u
r
a
t
e
d
f
a
t
t
y
-
a
c
i
d
a
m
i
d
e
m
e
t
a
b
o
l
i
z
e
d
b
y
F
A
A
H
/
N
A
A
A
,
c
o
a
d
m
i
n
i
s
t
r
a
t
i
o
n
w
i
t
h
F
A
A
H
i
n
h
i
b
i
t
o
r
s
o
r
o
t
h
e
r
N
-
a
c
y
l
e
t
h
a
n
o
l
a
m
i
n
e
s
(
P
E
A
,
a
n
a
n
d
a
m
i
d
e
-
m
o
d
u
l
a
t
i
n
g
a
g
e
n
t
s
)
c
o
u
l
d
a
l
t
e
r
i
t
s
l
e
v
e
l
s
,
t
h
o
u
g
h
c
l
i
n
i
c
a
l
r
e
l
e
v
a
n
c
e
i
s
u
n
k
n
o
w
n
.
A
n
y
o
n
e
o
n
p
r
e
s
c
r
i
p
t
i
o
n
m
e
d
i
c
a
t
i
o
n
,
p
a
r
t
i
c
u
l
a
r
l
y
f
o
r
d
i
a
b
e
t
e
s
,
l
i
p
i
d
s
,
o
r
m
e
t
a
b
o
l
i
c
d
i
s
e
a
s
e
,
s
h
o
u
l
d
c
o
n
s
u
l
t
a
c
l
i
n
i
c
i
a
n
b
e
f
o
r
e
u
s
e
.

Who should avoid it

Pregnant or breastfeeding individuals (no established safety data)
Anyone on glucose- or lipid-lowering medication without clinician oversight, given theoretical additive metabolic effects
People with significant liver disease (OEA undergoes hepatic first-pass metabolism and metabolic-pathway effects are not characterized in this population)
Those expecting a potent or reliable weight-loss drug; demonstrated human effects are modest and evidence is limited
Anyone relying on unverified products without a certificate of analysis, given lack of regulatory quality assurance

How it is commonly combined

Stacking claims for OEA are largely marketing-driven and not backed by controlled human combination trials. It is sometimes paired with palmitoylethanolamide (PEA), a related N-acylethanolamine, on the rationale that they share the NAE family and metabolic enzymes, but coadministration data are preclinical at best. It is also bundled into appetite/weight "fat-loss" formulas alongside ingredients such as caffeine or berberine; no rigorous human evidence supports these specific combinations for added efficacy or confirms their combined safety. Because OEA is metabolized by FAAH/NAAA, combining it with agents that inhibit those enzymes could unpredictably raise its levels. There is no evidence-based stack this site can endorse; combinations should be discussed with a clinician.

Legal & regulatory. In the United States, OEA is an endogenous lipid marketed as a dietary supplement ingredient. A New Dietary Ingredient (NDI) notification was filed with the FDA and receipt was acknowledged around 2015; acknowledgment of an NDI notification is a procedural step, not FDA "approval," and does not constitute an endorsement of safety or efficacy. OEA is not an FDA-approved drug and holds no approved therapeutic indication. In the European Union it is not an authorized novel food, so it cannot be lawfully sold there as a food or food supplement without going through the Novel Food authorization process. Structure/function marketing (for example "supports satiety") is permitted in the US; disease-treatment claims are not. Informational only, not legal advice, and status can differ by jurisdiction and change over time.

Quality & harm reduction

B
e
c
a
u
s
e
O
E
A
i
s
s
o
l
d
a
s
a
d
i
e
t
a
r
y
s
u
p
p
l
e
m
e
n
t
r
a
t
h
e
r
t
h
a
n
a
p
h
a
r
m
a
c
e
u
t
i
c
a
l
,
p
r
o
d
u
c
t
q
u
a
l
i
t
y
i
s
n
o
t
g
u
a
r
a
n
t
e
e
d
b
y
a
n
y
r
e
g
u
l
a
t
o
r
a
n
d
v
a
r
i
e
s
b
y
m
a
n
u
f
a
c
t
u
r
e
r
.
P
u
r
i
t
y
,
a
c
t
u
a
l
O
E
A
c
o
n
t
e
n
t
v
e
r
s
u
s
l
a
b
e
l
c
l
a
i
m
,
a
n
d
f
r
e
e
d
o
m
f
r
o
m
o
x
i
d
a
t
i
o
n
(
O
E
A
i
s
a
n
u
n
s
a
t
u
r
a
t
e
d
l
i
p
i
d
a
n
d
c
a
n
d
e
g
r
a
d
e
)
a
r
e
t
h
e
p
r
a
c
t
i
c
a
l
c
o
n
c
e
r
n
s
.
L
o
o
k
f
o
r
p
r
o
d
u
c
t
s
w
i
t
h
t
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
a
n
d
a
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
c
o
n
f
i
r
m
i
n
g
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
;
s
o
m
e
s
u
p
p
l
i
e
r
s
m
a
r
k
e
t
d
e
f
i
n
e
d
-
p
u
r
i
t
y
p
o
w
d
e
r
(
f
o
r
e
x
a
m
p
l
e
h
i
g
h
-
p
e
r
c
e
n
t
a
g
e
a
s
s
a
y
s
)
w
i
t
h
h
e
a
v
y
-
m
e
t
a
l
a
n
d
m
i
c
r
o
b
i
a
l
t
e
s
t
i
n
g
.
F
o
r
m
u
l
a
t
i
o
n
m
a
t
t
e
r
s
b
e
c
a
u
s
e
o
r
a
l
b
i
o
a
v
a
i
l
a
b
i
l
i
t
y
i
s
i
n
h
e
r
e
n
t
l
y
l
i
m
i
t
e
d
;
s
u
b
l
i
n
g
u
a
l
,
l
i
p
i
d
-
b
a
s
e
d
,
o
r
m
i
c
r
o
n
i
z
e
d
f
o
r
m
a
t
s
a
r
e
m
a
r
k
e
t
e
d
o
n
b
i
o
a
v
a
i
l
a
b
i
l
i
t
y
g
r
o
u
n
d
s
b
u
t
t
h
e
c
o
m
p
a
r
a
t
i
v
e
h
u
m
a
n
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
e
v
i
d
e
n
c
e
i
s
w
e
a
k
.
N
o
t
e
t
h
a
t
p
r
o
p
r
i
e
t
a
r
y
"
f
a
t
-
l
o
s
s
"
b
l
e
n
d
s
m
a
y
u
n
d
e
r
-
d
o
s
e
t
h
e
a
c
t
u
a
l
O
E
A
.
V
e
r
i
f
y
t
h
e
l
a
b
e
l
l
i
s
t
s
o
l
e
o
y
l
e
t
h
a
n
o
l
a
m
i
d
e
s
p
e
c
i
f
i
c
a
l
l
y
,
n
o
t
m
e
r
e
l
y
a
g
e
n
e
r
i
c
"
f
a
t
t
y
a
c
i
d
"
b
l
e
n
d
.

Safer, legal alternative we recommend

Big Berb Energy. For a natural approach to the same metabolic/blood-sugar goal, our Berberine is a well-studied legal supplement.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Does OEA actually cause weight loss in humans?

Several small randomized controlled trials, mostly in obese adults and largely from a limited set of research groups, report modest reductions in body weight, BMI, waist circumference, and appetite over 6 to 8 weeks. A 2025 meta-analysis found generally favorable but small cardiometabolic effects while flagging few trials, small samples, short durations, and limited geographic diversity. It is not a potent or well-established weight-loss drug, and effects are modest.

Is OEA the same thing as the endocannabinoids or CBD?

No. OEA is an N-acylethanolamine structurally related to the endocannabinoid anandamide, but it does not meaningfully activate cannabinoid receptors and is unrelated to CBD. Its main characterized target is PPAR-alpha, a nuclear receptor governing lipid metabolism and satiety, which is a different mechanism from cannabinoid signaling.

Is OEA legal and is it FDA approved?

In the US, OEA is sold as a dietary supplement ingredient and an NDI notification was acknowledged by the FDA around 2015, but that is a procedural acknowledgment, not drug approval or an efficacy endorsement. It is not an FDA-approved drug. In the EU it is not an authorized novel food and cannot be lawfully sold as a supplement there without novel food authorization.

How much OEA is used in studies, and what should I take?

This site does not give dosing guidance. For context only, human trials commonly used about 125 mg twice daily (roughly 250 mg/day) orally for 6 to 8 weeks. Whether and how to use OEA, and at what amount, is a decision to make with a qualified clinician who knows your health history and medications.

Is OEA safe?

Short human trials report good tolerability with uncommon, generally mild side effects such as headache or sleep disturbance, and its status as a molecule the body makes naturally is reassuring in principle. However, there are no large or long-term human safety studies, and safety in pregnancy, breastfeeding, children, or liver/kidney disease is not established. Treat the long-term safety picture as unproven.

Does oral OEA even get absorbed and reach the brain?

Oral bioavailability is expected to be low because OEA undergoes substantial first-pass hepatic metabolism and rapid enzymatic breakdown by FAAH and NAAA. Its satiety effect is thought to act mainly peripherally (intestinal PPAR-alpha and vagal signaling to brainstem/hypothalamic circuits) rather than through direct brain penetration; a 2023 review framed this open question as whether OEA works centrally at all, favoring a largely peripheral mechanism.

References & further reading

PubMed: oleoylethanolamide PPAR-alpha satiety Fu Piomelli 2003
PubMed: oleoylethanolamide PPAR-alpha appetite body weight obese clinical trial
PubMed: oleoylethanolamide supplementation cardiometabolic systematic review meta-analysis randomized controlled trials
PubMed: oleoylethanolamide small intestine CD36 food intake formation degradation
ClinicalTrials.gov: oleoylethanolamide supplement healthy volunteers